Wird geladen...
Post-licensure Surveillance of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Children 6 weeks–59 months old, Vaccine Adverse Event Reporting System (VAERS), United States, 2010–2017
BACKGROUND: In February 2010, the Food and Drug Administration (FDA) licensed the 13-valent pneumococcal conjugate vaccine (PCV13) for use in children aged 6 weeks through 59 months. The Advisory Committee on Immunization Practices (ACIP) recommended routine use of PCV13 for all children ages 2, 4,...
Gespeichert in:
| Veröffentlicht in: | Open Forum Infect Dis |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Oxford University Press
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5631011/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.1184 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|